aTyr Pharma, Inc.
LIFEDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Efzofitimod 3 mg/kg
Pulmonary Sarcoidosis
ATYR1940
Limb-Girdle Muscular Dystrophies
efzofitimod 450 mg
Interstitial Lung Disease
Efzofitimod 1 mg/kg
SARS-CoV-2 (COVID-19) Severe Pneumonia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Efzofitimod 3 mg/kg | Phase 3 | Pulmonary Sarcoidosis | - | - |
ATYR1940 | Phase 2 | Limb-Girdle Muscular Dystrophies | - | - |
efzofitimod 450 mg | Phase 2 | Interstitial Lung Disease | - | - |
Efzofitimod 1 mg/kg | Phase 2 | SARS-CoV-2 (COVID-19) Severe Pneumonia | - | - |
Frequently asked questions
What is in aTyr Pharma, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in aTyr Pharma, Inc.'s (LIFE) pipeline across Phase 3, Phase 2. Its lead program is Efzofitimod 3 mg/kg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is aTyr Pharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for aTyr Pharma, Inc. (LIFE) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LIFE biotech catalysts?→
Add LIFE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow aTyr Pharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.